This adaptive response promotes tumor survival, angiogenesis, metastasis, and resistance to therapy, making HIFs crucial targets for cancer treatment strategies. Treatment with β-CT-ZnO NPs significantly suppressed HIF expression in a dose-dependent manner. Here, PCYT1B is linked to neoplasm.